Analyst Reco. RAPT Therapeutics, Inc.

Equities

RAPT

US75382E1091

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
4.01 ^USD	-0.99%		-4.07%	-83.86%

May. 14	Wolfe Research Downgrades RAPT Therapeutics to Peer Perform From Outperform	MT
May. 10	Guggenheim Downgrades RAPT Therapeutics to Neutral From Buy	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Wolfe Research Downgrades RAPT Therapeutics to Peer Perform From Outperform	May. 14	MT
Guggenheim Downgrades RAPT Therapeutics to Neutral From Buy	May. 10	MT
Barclays Downgrades RAPT Therapeutics to Equalweight, Price Target at $4	May. 10	MT
JPMorgan Lowers RAPT Therapeutics' Price Target to $13 From $15, Keeps Neutral Rating	Mar. 27	MT
UBS Downgrades RAPT Therapeutics to Neutral From Buy, Adjusts Price Target to $10 From $61	Feb. 22	MT
Barclays Adjusts Price Target on RAPT Therapeutics to $13 From $35, Maintains Overweight Rating	Feb. 21	MT
Leerink Partners Downgrades RAPT Therapeutics to Market Perform From Outperform, Price Target is $10	Feb. 21	MT
HC Wainwright Downgrades RAPT Therapeutics to Neutral From Buy	Feb. 21	MT
JPMorgan Downgrades RAPT Therapeutics to Neutral From Overweight, Price Target is $15	Feb. 21	MT
Stifel Cuts RAPT Therapeutics' Price Target to $33 From $40, Keeps Buy Rating	Feb. 20	MT
Piper Sandler Cuts RAPT Therapeutics' Price Target to $18 From $31, Keeps Overweight Rating	Feb. 20	MT
Cantor Fitzgerald Downgrades RAPT Therapeutics to Neutral From Overweight	Feb. 20	MT
Evercore ISI Starts Coverage on RAPT Therapeutics With Outperform Rating	Feb. 16	MT
Wolfe Research Starts RAPT Therapeutics With Outperform Rating, $39 Price Target	Feb. 15	MT
RAPT Therapeutics, Inc. Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC	Nov. 03	CI
Berenberg Initiates RAPT Therapeutics With Buy Rating, Price Target is $34	23-09-14	MT
JPMorgan Adjusts Price Target on RAPT Therapeutics to $32 From $39, Maintains Overweight Rating	23-08-16	MT
Piper Sandler Adjusts Price Target on RAPT Therapeutics to $31 From $28, Maintains Overweight Rating	23-08-14	MT
Stifel Initiates Coverage on RAPT Therapeutics with Buy Rating, $40 Price Target	23-08-09	MT
Barclays Initiates RAPT Therapeutics With Overweight Rating, $35 Price Target	23-06-15	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. RAPT Therapeutics, Inc.

Equities

RAPT

US75382E1091

Analyst Reco.

Filters